(PubMed) Knekt P, Ritz J, Pereira MA, et al
In 2024, NICE issued draft guidance supporting tirzepatide for obesity in adults with a BMI of at least 35 kg/m2, and with at least one weight-related comorbidity, while recommending phased rollout and continued review
Bioavailability and absorption represent the primary clinical consideration with oral tirzepatide
Final Thoughts GLP-1 medications can be powerful tools, but they are not a cure-all
B12 deficiency neuropathy can mimic diabetic neuropathy and may involve the upper limbs
If your insurance covers weight loss medications, Ro can help you navigate the prior authorization process and potentially access brand-name medications at your insurance copay rate